UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for pancreatic cancer in the United Kingdom. Explore treatment pathways including surgery, chemotherapy, and emerging therapies.
Pancreatic cancer affects ~10,500 people per year in the UK and is the 5th most common cause of cancer death. It often presents late with vague symptoms (jaundice, back pain, weight loss), making early diagnosis challenging. Survival rates are improving but remain lower than most cancers - 1-year survival is ~25%. Research is focused on earlier detection and more effective treatments.
Operable (~10%): surgery (Whipple procedure or distal pancreatectomy) followed by adjuvant chemotherapy. Borderline operable: neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine + nab-paclitaxel) to shrink the tumour before surgery. Locally advanced: chemotherapy ± radiotherapy. Metastatic: FOLFIRINOX or gemcitabine + nab-paclitaxel. For BRCA-mutated tumours, maintenance olaparib (PARP inhibitor) can extend survival.
New approaches showing promise include: KRAS G12C inhibitors (sotorasib, adagrasib) for the ~2% with this mutation, KRAS G12D targeted therapies, immunotherapy combinations for MSI-H tumours (~1-2%), oncolytic viruses, and stroma-modifying agents to improve drug delivery. The NHS is investing in rapid diagnostic centres for earlier pancreatic cancer detection.
The UK has dedicated pancreatic cancer trials through the NHS and charities like Pancreatic Cancer UK. Active areas: neoadjuvant immunotherapy, adaptive chemotherapy based on early response, circulating tumour DNA monitoring, CAR-T cell therapy, and cancer vaccines. The Precision-Panc programme matches patients to trials based on molecular profiling.
Free AI-powered matching - no signup required
Search pancreatic ductal adenocarcinoma Trials →